Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

2.

Glutamate-based therapeutic approaches: NR2B receptor antagonists.

Gogas KR.

Curr Opin Pharmacol. 2006 Feb;6(1):68-74. Epub 2005 Dec 22. Review.

PMID:
16376149
3.

Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia.

Joppa MA, Ling N, Chen C, Gogas KR, Foster AC, Markison S.

Peptides. 2005 Nov;26(11):2294-301. Epub 2005 Mar 25.

PMID:
16269355
4.

Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines.

Tucci FC, White NS, Markison S, Joppa M, Tran JA, Fleck BA, Madan A, Dyck BP, Parker J, Pontillo J, Arellano LM, Marinkovic D, Jiang W, Chen CW, Gogas KR, Goodfellow VS, Saunders J, Foster AC, Chen C.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4389-95.

PMID:
16098742
5.

1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists.

Huang CQ, Baker T, Schwarz D, Fan J, Heise CE, Zhang M, Goodfellow VS, Markison S, Gogas KR, Chen T, Wang XC, Zhu YF.

Bioorg Med Chem Lett. 2005 Aug 15;15(16):3701-6.

PMID:
16005225
6.

In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic.

Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, Bozigian HP, Gross RS, Gogas KR.

J Pharmacol Exp Ther. 2004 Nov;311(2):547-59. Epub 2004 Jul 15.

PMID:
15256538
7.

Body weight regulation by selective MC4 receptor agonists and antagonists.

Foster AC, Joppa M, Markison S, Gogas KR, Fleck BA, Murphy BJ, Wolff M, Cismowski MJ, Ling N, Goodfellow VS, Chen C, Saunders J, Conlon PJ.

Ann N Y Acad Sci. 2003 Jun;994:103-10. Review.

PMID:
12851304
8.

Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions.

Novakovic SD, Tzoumaka E, McGivern JG, Haraguchi M, Sangameswaran L, Gogas KR, Eglen RM, Hunter JC.

J Neurosci. 1998 Mar 15;18(6):2174-87. Review.

9.

The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.

Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, Fontana DJ.

Eur J Pharmacol. 1997 Apr 18;324(2-3):153-60.

PMID:
9145766
10.

PN3 sodium channel distribution in the dorsal root ganglia of normal and neuropathic rats.

Tzoumaka E, Novakovic SD, Haraguchi M, Sangameswaran L, Wong K, Gogas KR, Hunter JC.

Proc West Pharmacol Soc. 1997;40:69-72. No abstract available.

PMID:
9436216
11.
12.
14.

Walking evokes a distinctive pattern of Fos-like immunoreactivity in the caudal brainstem and spinal cord of the rat.

Jasmin L, Gogas KR, Ahlgren SC, Levine JD, Basbaum AI.

Neuroscience. 1994 Jan;58(2):275-86.

PMID:
8152539
15.

Mechanisms of opioid-mediated antinociception: correlation of Fos expression and behavior.

Gogas KR, Levine JD, Basbaum AI.

NIDA Res Monogr. 1993;125:134-60. Review. No abstract available.

PMID:
8341362
16.
18.

A role for histamine and H2-receptors in opioid antinociception.

Gogas KR, Hough LB, Eberle NB, Lyon RA, Glick SD, Ward SJ, Young RC, Parsons ME.

J Pharmacol Exp Ther. 1989 Aug;250(2):476-84.

PMID:
2547933
19.

Inhibition of naloxone-resistant antinociception by centrally administered H2-antagonists.

Gogas KR, Hough LB.

J Pharmacol Exp Ther. 1989 Jan;248(1):262-7.

PMID:
2563290
20.

Actions of the brain-penetrating H2-antagonist zolantidine on histamine dynamics and metabolism in rat brain.

Hough LB, Jackowski S, Eberle N, Gogas KR, Camarota NA, Cue D.

Biochem Pharmacol. 1988 Dec 15;37(24):4707-11.

PMID:
3202904
21.

H2-receptor-mediated stress-induced analgesia is dependent on neither pituitary nor adrenal activation.

Gogas KR, Hough LB.

Pharmacol Biochem Behav. 1988 Jul;30(3):791-4.

PMID:
2905473
22.
23.
24.

Supplemental Content

Loading ...
Support Center